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1. Introduction
Pancreatitis is an inflammatory acute or chronic disease of the pancreas. Although etiology of
acute and chronic pancreatitis remains poorly defined, so far a variety of environmental,
hereditary and immunological factors and bile duct obstructions have been described.
Treatment of patients suffering from severe acute pancreatitis (AP) remains challenging, and
despite improved strategies, mortality is still between 30 and 50 % [1]. The prognosis of patients
with acute pancreatitis is largely determined by the presence of organ failure and infected
pancreatic necrosis with associated mortality rates of 15%-30% [2].
AP is an inflammatory disease of the pancreas characterized by edema, acinar cell necrosis,
hemorrhage and severe inflammation of the pancreas [3,4] and some of the other organs
including liver [3,5]. Some inflammatory factors including interleukin (IL)-1, IL-6, IL-8, C-
reactive protein, tumor necrosis factor (TNF), nitric oxide (NO) and endothelin are suggested
to be involved in the genesis and progression of AP as well as in the progression from slight
AP to severe AP [6]. By electron microscopic observation, dilatation of irregularly arranged
cisternae of rough endoplasmic reticulum and of some of the cisternae of Golgi apparatus are
prominent. The mitochondria with increased translucence of the matrix, partial destruction or
loss of the cristae are edematous. Sometimes myelin figures are observed within the mito‐
chondrial matrix. Numerous, large autophagosomes containing amorphous, membranous or
granular masses and zymogen granules are present within the cytoplasm (Figure 1,2). Nuclear
chromatin clumping and margination indicating apoptosis are present [4] (Figure 2).
Chronic  pancreatitis  (CP)  characterized  by  fibrosis,  and  pain  is  a  long-standing  inflam‐
mation  of  the  pancreas  that  alters  its  normal  structure  and  functions.  Regions  of  the
pancreas  are  transformed  from  glandular  tissue  to  a  mass  of  almost  complete  fibrosis.
The secretory parenchyma is destroyed by processes such as necrosis/ apoptosis, inflam‐
mation  or  duct  obstruction.  Pancreatic  stallate  cells  present  in  the  periacinar  space  and
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Figure 1. Mitochondral edema and degeneration, and accumulation lysosomes containing identifiable cytoplasmic ele‐
ments, amorphous, membranous or granular masses are observed in the cytoplasm of an acinar cell in cerulein-in‐
duced experimental acute pancreatitis. X 10.000
Figure 2. Nuclear chromatin clumping and margination indicating apoptosis, and organelle degeneration as well as
lysosome accumulation are observed in the cytoplasm of acinar cells in cerulean-induced experimental acute pancrea‐
titis. Note that apoptotic cell is engulfed by a neighboring acinar cell. X 8.000
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have  long  cytoplasmic  processes  that  encircle  the  base  of  the  acinus  are  strongly  in‐
volved  not  only  in  the  pathogenesis  of  CP  but  also  in  pancreatic  cancer.  They  are  lo‐
cated  in  the  periacinar,  perivascular  and  periductal  regions  of  the  pancreas  [7,  8].
Over the past decades, our understanding of the pathogenesis of pancreatitis has significantly
improved. Animal models including caerulein, taurocholate, L-arginine studies are important
in order to understand the pathogenesis of pancreatitis, however none of them are fully
satisfactory. It is now widely accepted that AP is triggered by premature activation of proen‐
zymes within pancreatic acinar cells, thereby leading to autodigestion of the pancreas.
Esrefoglu et al [3,4,9] emphasized the role of oxidative stress on the pathogenesis of careulein-
induced pancreatitis. They showed potent therapeutic effects of some antioxidant agents
including melatonin, ascorbic acid and N-acetyl cysteine on AP in rats. In fact, in recent years,
valuable data on the efficiency of antioxidants against oxidative damage have been obtained
from experimental studies with rodents. With the inspiration of the results of these experi‐
ments, efficiency of some of these antioxidants has been tried on the patients with AP and
found beneficial. However, at present there is insufficient clinical data to support the benefits
of antioxidants, alone or in combination with conventional therapy, in the management of AP
in humans [10]. The effects of stem cells transplantation on tissue oxidative stress level have
been studied lately. In fact, stem cell transplantation helps to maintain tissue regeneration by
replacing the degenerated cells as well as by regulating oxidative stress production. Stem cells
have been shown to be able to scavenge reactive oxygene and nitrogen species, and to limit
oxidative stress-induced tissue damage [11]. Recently, mesenchymal stem cells have been
found beneficial in a traumatic brain injury in vitro model and myocardial ischemia/reperfu‐
sion model decreasing oxidative stress levels by their paracrine effects [12,13]. Mesenchymal
stem cells have been shown to increase tissue SOD, activity but decrease tissue MDA level on
AP in rats [14].
Development of evidence based therapies for pancreatitis has lagged behind advances in
understanding of the pathophysiology of the disease. Herein, no pharmacologic therapy has
been shown to affect disease progression. Several potential reasons for the lack of progress in
development of treatments for pancreatitis includes a lack of sustained effort to transition basic
science findings into clinical trials and a lack of appropriate preclinical models for testing
potential therapeutic agents. In recent years, the efficacy of stem cell transplantation applica‐
tions is widely investigated in the course of several diseases in experimental animals and also
in humans. In pancreatitis, stem cells might recover the damaged pancreatic tissue by their
excessive proliferating and differentiating capabilities and regulatory functions on oxidative
stress levels under the regulatory control of the microenviroment. Unfortunately, the results
obtained from rodents studies might not be similiar to those obtained from human studies.
Herein I tried to review the results of stem cell transplantation therapies obtained from rodent
and human studies on AP and CP. However, I realize that although researchers agree about
the therapeutic potency of transplanted progenitor and stem cells on acute and chronic
pancreatitis, any clinical trial has been performed so far.
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2. Catagorization of stem cells
Stem cells are different from the other cell types since they are unspecialized cells that are
capable of changing themselves into various types of specialized cells. The main features of
stem cells are the capability to divide, proliferate, and self-renewal; to differentiate to one or
several cell types and to survive in an undifferentiated stage for a while. In fact, they may
remain in such an undifferentiated state for long time periods. When the morphological as
well as functional differentiation begins, these cells differentiate into multiple specialized cell
lineages. One stem cell may divide into two identical stem cells by symmetrical division or it
may divide into one stem cell and one progenitor cell by asymmetrical division. One progenitor
cell also may divide into identical progenitor cells by symmetrical division. The committed
progenitor cells exhibit a capacity to give rise to terminally differentiated cells under favorable
influences which are not fully known yet.
Stem cells are classified depending on the potential for differentiation into specialized cell
types. The most capable stem cells which are totipotent cells of the zygote within first 4 days
of the intrauterine life are able to form a full organism in appropriate microenvironment.
However, pluripotent cells, known as ‘embryonic stem cells’(ESCs), principally derived from
the inner cell mass of the embryo can form virtually any cell type derived from any of three
embryonic germ layers; ectoderm, mesoderm or endoderm. Thus, an embryonic stem cell can
form enterocyte (endodermal in origin), cardiomyocyte (mesodermal in origin), and kerati‐
nocyte (ectodermal in origin). Surplus embryos obtained from in-vitro fertilization laboratories
are the main sources of the ESCs. However, some disadvantages including high immune
reaction risk and some ethical concerns limit their applications. The third type of stem cells is
multipotent stem cells which are also known as ‘adult stem cells’. These cells with a relatively
limited differentiation potential can form several cell types of the tissue. These cells reside
together with the specialized cell types of the adult tissues and they are thought to be respon‐
sible for the tissue maintenance and repair. The exact mechanisms that affect them to stay in
undifferentiated stage for a period of time and force them to differentiate into a specialized
cell type are not fully known yet. The two major populations of adult stem cells are bone
marrow mesenchymal and hematopoietic stem cells (HSCs). Hematopoietic stem cells have a
predetermined fate to form all types of the mature blood cells. Mesenchymal stem cells can
differentiate into multiple cell lineages, including tendon cells, muscle cells, osteocytes, fat
cells etc. The term ‘multipotent stromal cell’ implies the multipotent stem cells of both bone
morrow and of none-morrow tissues such as umbilical cord blood, adipose tissue, muscle
tissue, dental pulp etc. Important data obtained from mainly cell culture studies have provided
clues about the ability of adult stem cells to differentiate into various cell types from different
germ layers. For instance; the HSCs which are derived from mesoderm can transform into
hepatocytes which are derived from endoderm or brain stem cells which are derived from
ectoderm can form skeletal muscle fibers which are derived from mesoderm. Multipotent cells
are genetically identical to their hosts, thus they don’t cause any immune reaction. However,
these cells are restricted in their ability to form different cell types in comparison with ESCs.
Moreover, they have some disadvantages including slow rate of cell division and difficulties
to isolate in sufficient numbers for application because of their sparsity within the tissues. The
Acute and Chronic Pancreatitis156
last type of stem cells is unipotent stem cells that have a very limited capacity for differentiation
and can give rise to only one type of cell under normal conditions. For instance; unipotent stem
cells of colony forming unit of erythrocytes (CFU-E) can only give rise to mature erythrocytes
of blood.
In recent years stem cells are widely studied for their promising potential therapeutic use in
both rodents and humans. However, some of the human studies failed to be successful.
Researchers agree that as well as isolation of adequate numbers of healthy stem cells, selection
of most convenient transporting route, regulation of stem cell differentiation into a special cell
type, and obtainment of the usual functions of the differentiated cells are very important
regarding the benefit of stem cell applications. The most important risk of the transplanted
stem cells is generation of tumors if cell division continues in an uncontrolled manner.
Unfortunately, the stem cell transplantation therapy may be considered as a sort of two-edged
sword.
2.1. Stem cells in exocrine pancreas
Identification of stem and/or progenitor cells in the adult pancreas has been an area of intense
investigation in the past decades, but the results remain controversial [15]. Determined stem
cells for pancreatic cell therapies have not been considered an option based on evidence that
there are no or only rare pancreatic stem cells in postnatal tissues [16]. Rare stem cell popula‐
tions have been identified within the pancreas and that express pluripotency genes (OCT4,
SOX2) [17-19]. The few studies in which OCT4 and SOX21 multipotent stem cells have been
identified in adult pancreas have indicated also their rarity [19]. Smukler et al [17] described
pancreas-derived multipotent cells, which are rare (1/5000 pancreas cells) and form spheres in
vitro. They can differentiate into multiple lineages, including several endocrine cell types and
neurons. Gong et al [20], using stem cell marker nestin, reported experimental clues supporting
the lack of primary stem cells in adult pancreas tissue. They suggested that the so-called
pancreatic stem cells may actually originate from bone marrow stem cells. When pancreatic
tissue is injured, bone marrow stem cells may participate in the repair.
The location of stem cells in each organ has been widely investigating. Wang et al [21] provide
evidence that the biliary tree is a reservoir of stem cells for the pancreas. They present evidence
to suggest the biliary tree and pancreatic networks are connected anatomically and function‐
ally to comprise maturational lineages relevant to pancreatic organogenesis. They showed that
determined stem cell populations, present throughout life, are precursors for pancreatic
committed progenitors in the pancreatic duct glands (a novel ductal compartment that is
gathered in gland-like outpouches), and are present in the ramifying, continuous network of
ducts and associated glands of the biliary tree.
The postnatal pancreas has long been thought to contain only committed progenitors, found
in pancreatic ducts [22,23] and, in the pancreatic duct glands [24]. These precursors are
reported to be limited in their proliferative and self-renewal potential. A recent study of
Stanger et al [25] suggested that the final size of the pancreas is also determined by the number
of embryonic progenitor cells, each with an autonomous restriction on the amount of tissue it
was capable of generating. Centroacinar cells and terminal duct cells lie at the junction between
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peripheral acinar cells and the adjacent ductal epithelium. Both of these cell types are supposed
to be candidate pancreatic progenitors. Specifically, these cells express high levels of Ptf1a,
Sox9, Sca-1, SDF-1, c-Met, and Nestin [26]. Magliano et al [27] have reported that although Sox9
is expressed throughout the pancreas epithelium, pancreatic ductal cells in the adult pancreas,
excluding acinar and centroacinar cells, it is reactivated in acinar cells that undergo de-
differentiation after induction of pancreatitis with cerulein. The findings suggest that at least
a subset of cells residing in a centroacinar/terminal ductal location is capable of progenitor
function. The finding that this population undergoes dramatic expansion during an epithelial
injury suggests that these cells are involved in pancreatic epithelial regeneration. Together
with their location at the junction between peripheral secretory cells and more central ductal
epithelium, these features suggest similarity between centroacinar/terminal ductal cells and
hepatic oval cells which are progenitor cell type capable of multilineage differentiation in the
event of any injury [28].
In the primary transition pancreas, primary stem cell type is multipotent stem cells, capable
of contributing to all epithelial cell lineages of the pancreas parenchyma. These cells coexpress
important transcription factors including Pdx1, Ptf1a, Nkx6.1, Hnf1β, and Sox9 [29-31]. During
the secondary transition period, pancreatic epithelium forms finger-like projections into the
surrounding mesenchyme generating a tree-like epithelial structure with recognizable ‘tip’
and ‘trunk’ segments [32,33]. The bipotential progenitor cell population within the trunk
segment seems to be progenitors of both endocrine and duct lineages [31,34,35]. Solar et al [34]
provided clues on the potency of these cells to contribute to the endocrine and ductal lineages
by genetic lineage tracing of Hnf1β positivity. Following their specification, endocrine
precursor cells leave the trunk compartment to form mature islets [36-38] whereas the
remaining cells that remain within the trunk contribute to the pancreatic duct [39]. Recently
we investigated prenatal and postnatal development of the rat pancreas as well as the other
organs of the digestive system (Unpublished data). At prenatal 10th day pancreas premordium
was composed of a few tubes lined with a simple epithelium and surrounding mesenchymal
tissue rich in vessels. Many mitotic figures were observed within the epithelium (Figure 3A).
At prenatal 14th day, branching of the tubes was prominent. The tips of the branhcing trunk
were formed as primitive acini (Figure 3B). The epithelium was still rich in mitosis. At prenatal
17th day, further branches gave rise to increased number of acini (Figure 3C). Endocrine cell
islets were observed at prenatal 17th day for the first time. However, at postnatal 15th day, it
was so clear that the same trunk gave rise to both exocrine and endocrine compartments of the
pancreas (Figure 3D).
Pancreatic regeneration involves two pathways; proliferation and differentiation of pancreatic
progenitor cells, and replication of preexisting differentiated acinar, islet, and ductal epithelial
cells [40]. Expression of transcription factors and cell differentiation are under the control of
some regulating signalling factors either secreted from neighbouring tissues or pancreatic
mesenchymal cells (e.g. fibroblast growth factors) [41,42] or are expressed on the surface of
differentiating pancreatic cells (e.g. Notch) [43]. Mammalian pancreas displays a significant
capacity for regeneration following injury. A variety of cell types have been proposed as
possible pancreatic progenitors, including cells associated with ductal epithelium [19],
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mesenchymal-like nestin expressing cells [44] and preexisting acinar cells [45]. Centroacinar
cells and terminal duct cells are frequently supposed to be candidate pancreatic progenitors.
These cells are markedly enriched for transcripts encoding Sca1, Sdf1, c-Met, Nestin, and Sox9
markers which were previously associated with progenitor populations in embryonic pan‐
creas. Fluorescent Activated Cell-Sorted centroacinar/terminal duct cells are shown to be able
to form self-renewing “pancreatospheres” in suspension culture. The progenitor cells of the
spheres have capacity for spontaneous endocrine and exocrine differentiation; additionally
they have ability to glucose-responsive insulin secretion. Moreover, when injected into
cultured embryonic dorsal pancreatic buds, these adult cells display capacity to contribute to
the embryonic endocrine and exocrine lineages. Finally, the number of these cells is shown to
be significantly increased in the setting of chronic epithelial injury [26].
Taguchi et al [40] observed newly formed acinar cells on day 7 following the induction of acute
necrotizing pancreatitis in rats. They reported that proliferation started in the main and large
Figure 3. The histological features of the pancreas during development. A. Prenatal 10th day. Pancreas premordium is
composed of a few tubes lined with a simple epithelium and surrounding mesenchymal tissue rich in vessels. Many
mitotic figures are observed within the epithelium. B. Prenatal 14th day. Branching of the tubes is prominent. The tips
of the branhcing trunk form primitive acini. C. Prenatal 17th day. Increased number of acini was formed by further
branches (red arrows). Many figures of mitosis are present within the epithelium (black arrows). D. Postnatal 15th day.
The same trunk gives rise to both exocrine and endocrine compartments of the pancreas.
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ducts at 24 h; marked mitotic activity was evident in small ductal epithelial cells and tubular
complexes on day 3, and in acinar cells on day 7. The lobular structure returned to normal
appearance on day 28. These results suggest that regeneration after necrotizing pancreatitis
involves proliferation and differentiation of pancreatic progenitor cells. Ductal epithelial cells
with duodenum homeobox protein 1 (PDX-1)-positive nuclei may contribute to the differen‐
tiation of the stem cells in the main duct of pancreas.PDX-1-positive cells in the main duct
might be quiescent pancreatic stem cells. PDX-1 might be a marker of cells that regain their
multipotency to differentiate into any pancreatic cell types [46], and is thought to be an intrinsic
signal determining the region of gut endoderm that ultimately becomes the pancreas [47].
PDX-1 has an important role in the determination of pancreatic progenitors [48] and neuro‐
genin-3 is required for determination of endocrine precursor [49].
3. Stem cell transplantation therapies
The use of stem cells for the treatment of various diseases in both humans and animals has
been the focus of considerable interest. Stem cell technology gives hope of effective treatment
for a variety of diseases through the rapid developing field that combines the efforts of cell
researchers and clinicians. However; it seems to be early to carry out a Bench-to-Bedside
program applying stem cell therapeutics in the clinical setting yet. Detailed researches are
necessary to understand the optimal transplantation routes and doses as well as the mecha‐
nisms of stem cell interaction with the injured microenvironment as clues for realizing stem
cell behavior.Stem cell therapy offers the possibility of repairing acutely or chronically injured
tissue and has the potential to regulate immune function and reduce inflammatory changes.
Recently, I reviewed the role of stem cells in repair of liver injury and experimental and clinical
benefit of transferred stem cells on liver failure [50]. I was suprised to recognize of how many
fundemantal and clinical trial on stem cell transplantation have been performed on acute and
chronic liver failure. In this chapter, I review cell types involved in pancreas regeneration and
cell transplantation therapies for both acute and chronic pancreatitis, with an emphasis on
regeneration. However, I realise that even fundamental studies are very limited. Adipose-
derived, bone marrow-derived and umblical cord-derived mesenchymal stem cells (MSCs)
have been subjected to the basic stem cell trials. To my knowledge any clinical trial has been
performed so far.
3.1. Mesenchymal stem cells
The MSCs, belong to a class of mesodermal adult stem cells population are found in numerous
living tissues including bone marrow, adipose tissue, amniotic fluid, liver, lung, skeletal
muscle and kidney. It has been reported that among MSCs obtained from bone marrow,
adipose tissue, umbilical cord blood and placenta could be expanded extensively in vitro. The
studies have confirmed that MSCs could differentiate into a range of cell types. For instance;
bone marrow derived MSCs could differentiate into a range of cell types such as adipocytes,
Acute and Chronic Pancreatitis160
osteoblasts, nerve cells, and liver cells under different conditions [51-53]. Additionally, the
experimental and clinical studies have shown that the MSCs could reduce the expression of a
variety of inflammatory factors [54,55], inhibit immune responses [56,57], and promote the
regeneration of various tissues and organs [58,59] including lung, kidney, liver and heart
[60-63]. Imunomodulatory functions of MCSs include suppression of T cell and B cell prolif‐
eration, and suppression of terminal differentiation of B cells, and immune modulation of other
cell of the immune system including NK cells and macrophages [64]. Here are the results
obtained from various trials related with stem cell transplantations on acute and chronic
pancreatitis.
3.1.1. Bone morrow derived MSCs
Bone marrow-derived MSCs harbor a biological basis which can be used as a candidate for
severe AP therapy. Cui et al [65] found transplanted and mobilized bone marrow stem cells
beneficial on mice with severe AP. They mobilized bone marrow stem cells by injection of
granulocyte colony stimulating factor. The mortality rate and serum level of amylase were
found to be significantly decreased in the mice pretreated with bone marrow-derived MSCs’
transplantation or G-CSF injection. Chen et al [66] injected 1x106 mL MSC via tail vein at 0th,
0th and 6th, 0th, 6th and 12th hours after AP induction by 5% sodium taurocholate injection
to biliopancreatic duct. After treatment with MSCs, the damage was less severe than that in
the untreated AP groups. Besides, MSCs therapy could improve renal injury in rats with severe
AP, probably by reducing the damage to renal interstitial capillary endothelial barrier, and
up-expression of AQP1 in kidney. Tu et al [14] reported that MSCs can effectively relieve injury
to pancreatic acinar cells and small intestinal epithelium. MSCs were shown to be able to
promote the proliferation of enteric epithelium and repair of the mucosa as well as to attenuate
systemic inflammation in rats with severe AP. Serum malondialdehyde (MDA) level was
reduced while superoxide dismutase (SOD) activity was increased the rats from AP + MSCs
group. They concluded that MSCs transplantation could reduce pancreatitis-related oxidative
injury by inhibiting lipid peroxidation, by protecting the stability of the membranes, and by
improving the scavenging ability of oxygen-derived free radicals. Recently, Sun et al [67]
intraperitoneally injected the third-generation bone marrow-derived MSC at a dose of 5×10(6)
once daily for 3 days. All rats were sacrificed after 72 h. Compared with severe AP group,
histomorphological alternations of small intestine were significantly lower in MSC injected
group. The relative expression quantity of TNF-α mRNA and IL-1β mRNA in small intestine
was both significantly higher in severe AP and MSC groups than those in control group.
Compared with AP group, the expression quantity of TNF-α mRNA and IL-1β mRNA in
pancreas was significantly lower in MSC group. The relative expression quantity of TNF-α
mRNA and IL-1β mRNA in small intestine were both significant higher in severe AP and MSC
groups than those in control group. The expressions of TNF-α mRNA and IL-1β mRNA in
MSC group were lower than those in severe AP group. The beneficial effects of MSCs seem to
be primarily mediated via indirect actions but not by their differentiation into target cells.
Wang et al [68] showed beneficial effects of bone marrow-derived MSCs on AP-associated lung
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injury in rats. Results showed that serum amylase activity was decreased and pulmonary
edema and the expression of TNF-α was significantly diminished in MSC transplanted group.
It has also been reported that autologous bone marrow MSCs can be used for the treatment of
CP.
It has been suggested that bone marrow-derived MSCs has a role in pancreatic tissue repair
by contribute to the pancreatic stellate cell population. In the absence of preneoplastic lesions,
these cells contribute at a very low level to the ductal epithelium of the chronically inflamed
pancreas [69]. MSCs are thought to alleviate pancreatic edema and inflammatory infiltration
by regenerating pancreatic cells. Jung et al [55] proposed that MSCs alleviate AP through
specific accumulation in injured pancreatic tissue rather than through cell regeneration. In this
study, inflammation was inhibited by promoting apoptosis of CD4+ T cells. Bone marrow-
derived MSCs reduced expression of inflammation mediators and cytokines in rats with mild
and severe AP. MSCs suppressed the mixed lymphocyte reaction and increased expression of
Foxp3(+) (a marker of regulatory T cells) in cultured rat lymph node cells. Rats with mild or
severe AP that were given infusions of hcMSCs had reduced numbers of CD3(+) T cells and
increased expression of Foxp3(+) in pancreas tissues. MSCs might alleviate pancreatitis by
regulating immune function rather than by regeneration of pancreatic tissue.
3.1.2. Adipose-derived MSCs
After in vivo administration, human adipose-derived stem cells (hADSCs) migrate into injured
tissue, where they inhibit the release of pro-inflammatory cytokines, promote the survival of
injured cells, and finally inhibit inflammation [70]. Baek et al [71] have shown that the migration
of hADSCs into injured/inflamed sites in vivo is mediated by various factors including growth
factors and chemokines. hADSCs would be a potential therapeutic strategy for AP, based on
its properties that control inflammation, immune response, and tissue repair. Further research
should focus on the interaction between hADSCs and pancreatic acinar cells, immune cells,
pancreatic stellate cells, and fibroblasts [72]. Although reserachers agree about the potency of
adipose-derived MSCs on tissue repair, to my knowledge, any related experimental and
clinical study has been reported so far.
3.1.3. Umblical cord-derived MSCs
The studies about the umblical-cord derived stem cells (UCMSCs) are also limited. Yang et
al [73] injected 5x104, 5x105 5x106 or 1x107 cells/kg of umblical cord stem cell suspension into
the tail vein at 0 h, 1 h, 6 h and 12 h after the induction of severe AP by sodium taurocholate
in rats. Mortality in rats receiving 5x106 cells/kg of UCMSCs at 0 h was 10% compared with
58% in the severe AP group. Ascites, serum amylase and wet-dry pancreatic weight signifi‐
cantly decreased. Pathologic injuries of pancreatic and pulmonary tissues were markedly
alleviated. Administration of umblical cord-derived MSCs at the doses of 5x105, 5x106 and
1x107 cells/kg at 1 h or 5x106 cells/kg at 6 h significantly reduced the severity of AP. The data
of the study of Yang et al [73] showed that UCMSCs cannot differentiate into other cells in 24
hours. The authors conclude that the prevention of damage has nothing to do with a differ‐
entiation of cells and that it seems to be a paracrine effect that can modulate immune function.
Acute and Chronic Pancreatitis162
UCMSCs may also be a promising therapeutic intervention for human CP in the future. In the
study of Zhou et al [74] a rat model of CP induced by dibutyltin dichloride (DB) was used.
UCMSCs were administered intravenously on day 5 after the administration of DB. UCMSCs
were detected in inflamed pancreatic tissues on days 14 and 28. Umbilical cord mesenchymal
stem cell treatment reduced the histological scores of pancreas samples and improved the
fibrosis. The expression of cytokines in the DB group was significantly higher than that of DB
+ UCMSC group. Pancreatic stellate cell activation was also inhibited by UCMSC treatment.
Stem cell types, dosages, application routes, main benefits and adverse reactions of stem cell
therapies on acute and chronic pancreatitis are summarized in Table 1.
 
 
Source 
(Country)  
Pancreatitis 
type 
Experimental 
design  
Species Stem cell 
type 
Dosage Route 
 
Sacrification 
time 
Examined 
organ/ 
organs 
Main benefits Adverse 
effects 
Cui et al; 2003 
China (Ref. 
no: 65)  
Severe AP L-arginin-
induced   
Female 
Balb/c mice 
Bone 
marrow-
derived 
MSC 
2x107; 4 days 
prior to SAP 
induction  
Tail vein 24th., 48th. and 
72th.after 
induction of 
SAP 
Pancreas    Mortality rate  
   Amylase level 
   Pathological changes 
 
Chen et al; 
2013 China 
(Ref. no: 66) 
Severe AP 5% sodium 
taurocholate-
induced 
Male 
Sprague-
Dawley rats 
Bone 
marrow-
derived 
MSC 
1ml 
(1x106/mL) at 
0. hour of SAP 
induction  
Tail vein 6th., 12th, 24th. 
hours after 
induction of 
SAP 
Pancreas 
Kidney 
    Amylase level 
    Creatine level  
    BUN level 
    Pathological 
changes  
US changes 
 
Tu et al;  
2012 China 
(Ref. no: 14) 
Severe AP Sodium 
deoxycholate-
induced 
Male 
Sprague-
Dawley rats 
Bone 
marrow-
derived 
MSC 
2ml (1× 106 
cells/mL) 2 
min after SAP 
induction 
Caudal vein 6th., 24th., 72th. 
hours after 
induction of 
SAP 
Pancreas 
cells (in 
culture) 
Small 
intestines 
   Amylase  
LD  level         
    MDA content 
Pathological 
changes 
    SOD activity    
 
Sun et al; 2013 
China (Ref. 
no: 67) 
Severe AP L-arginin-
induced   
Male 
Sprague-
Dawley rats 
Bone 
marrow-
derived 
MSC 
5×106, once 
daily for 3 
days 
Peritoneal  72th. hour after 
induction of 
SAP 
Pancreas 
Small 
intestines 
TNF-α mRNA 
IL-1β mRNA 
Pathological 
changes 
 
Wang et al; 
2012 China 
(Ref. no: 68) 
 
Severe AP 5% sodium 
taurocholate-
induced 
Male 
Sprague-
Dawley rats 
Bone 
marrow-
derived 
MSC 
1 ml 
(1×106/mL), 2 
hours after 
SAP induction 
Injection 1th., 3th., 6th., 12th. 
and 24th. hours 
after induction 
of SAP 
Lung     Amylase level 
    MPO level 
TNF-α  
Substance P 
Pathological 
changes 
 
Marrache et 
al; 2008 USA 
(Ref. no: 69) 
Severe CP Cerulein-
induced 
Female 
C57BL/6 rats 
Bone 
marrow-
derived 
progenitor 
cells 
Total 5×106 
bone marrow 
cells, 4 weeks 
before CP 
induction 
Tail vein 0, 6, 20, 30, 45 
weeks after CP 
induction 
Pancreas    Pathological 
changes 
Eosinophilic 
metaplasia (a 
reactive 
change to 
BMT) 
 
Yang et al; 
2013 China 
(Ref. no: 73) 
Severe AP Sodium 
taurocholate-
induced 
Male 
Sprague-
Dawley rats 
Umbilical 
cord-derived 
MSC 
5x104- 5x106, 
1x107 cells/kg 
of UCMSC 
suspension 
Tail vein 48 hours after 
AP induction 
Pancreas 
Lung 
Mortality rate 
Amylase level 
Ascite  
TNF-α 
Interferon-γ  
Pathological  
changes 
 
Zhou et al; 
2013 China 
(Ref. no: 74) 
Severe CP Dibutyltin 
dichloride-
induced 
Male 
Sprague-
Dawley rats 
Umbilical 
cord-derived 
MSC 
2×106  
UCMSCs in 
100 μL of PBS 
on day 5 after 
CP induction 
Jugular vein On days 14th and 
28th  after CP 
induction 
Pancreas     Amylase level 
    Pathological 
changes 
    Fibrosis 
 
 
AP: Acute pancreatitis, BMT: Bone marrow transplantation, BUN: Blood urea nitrogen, CP: Chronic pancreatitis, IL:
Interleukin, LD: Lactate dehydrogenase, MDA: Malondialdehyde, MPO: Myeloperoxidase, MSC: Mesenchymal stem cell,
SAP: Severe acute pancreatitis, SOD: Superoxide dismutase, TNF: Tumor necrosis factor, UCMSC: Umblical cord
mesenchymal stem cell, US: Ultrastructural
Table 1. A brief summary of characteristics of included studies
As a conclusion, although stem cell transplantation to patients with acute or chronic pancrea‐
titis has not been performed so far, it is clear that stem cell transplantation might be a promising
therapeutic approach for acute and chronic pancreatitis in the very near future.
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